Please login to the form below

Not currently logged in
Email:
Password:

TS23

This page shows the latest TS23 news and features for those working in and with pharma, biotech and healthcare.

Daiichi Sankyo licenses clot-busting antibody

Daiichi Sankyo licenses clot-busting antibody

The drug candidate - called TS23 - is in phase I trials but has shown "exceptional efficacy and safety in multiple disease models", according to Memphis-based Translational Sciences. ... It will pay Translational Sciences unspecified fees, milestones and

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
"Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....

Infographics